Navigation Links
CMX001 Shows Antiviral Activity in Immunocompromised Transplant Patients With Severe Adenovirus Infection
Date:5/11/2011

DURHAM, N.C., May 11, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing oral antiviral therapeutics, today presented data showing that the majority of immunocompromised patients with severe adenovirus infections who were treated with Chimerix’s lead antiviral compound, CMX001, had a > 99% decrease in viral load compared to baseline after two weeks of therapy.  These CMX001 clinical data, described in an oral presentation today at the 24th Annual International Conference on Antiviral Research (ICAR) held in Sofia, Bulgaria, demonstrate the unique activity of CMX001 against adenovirus (AdV), a life-threatening viral infection without an approved treatment.  

“In the most challenging and urgent of Emergency IND cases, CMX001 has demonstrated antiviral activity against a full spectrum of double-stranded DNA infections including AdV,” said Wendy Painter, MD, Chief Medical Officer for Chimerix. “The results presented in this oral session today further support our efforts to advance CMX001 as a much-needed therapeutic for critically ill transplant patients, including pediatric post-stem cell transplantation patients with life-threatening adenovirus infections.  We also believe that this data will contribute to broader development of CMX001 against the breadth of double-stranded DNA viruses.”  

Chimerix’s CMX001 is in development as a potential broad-spectrum antiviral agent with promising activity against all classes of double-stranded DNA (dsDNA) viruses that can infect humans.  CMX001 is currently in clinical studies against multiple infections including cytomegalovirus and advenovirus, and has the potential to meet a significant unmet medical need for patients at risk of these dsDNA life-threatening viral infections.

The oral presentation provided an analysis of twenty-two patients with adenovirus viremia who had received at least two doses of CMX001, had measu
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerixs Lead Antiviral CMX001
2. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
3. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
4. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
5. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
6. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
7. New Device to Support Blood Circulation for Heart Patients Shows Improved Outcomes Compared to Current Treatment
8. Study Shows Same Day PET-Guided Biopsy May Expedite Pre-Operative Work-up For Breast Cancer Patients and Reduce Radiation Exposure
9. Chronic Disease Research Group Study Shows Daily Home Hemodialysis Therapy with the NxStage® System One™ is Associated with Lower Risk of Mortality and Higher Survival Estimates Compared to Conventional Thrice-Weekly Dialysis
10. Tissue Engineering Shows Promise to Revolutionize Transplant Medicine
11. Phase I Research of Extended-Release Topiramate Shows Less Fluctuation in Plasma Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
(Date:5/21/2013)... 2013  BioRestorative Therapies, Inc. ("BRT" or the "Company") ... developing stem cell based therapies for various personal applications, ... President and CEO, will be presenting at the Marcum ... held on Thursday, May 30, 2013 at the Grand ... New York City.  Mr. Weinreb,s presentation will take place ...
(Date:5/21/2013)... , May 21, 2013 STAAR Surgical Company ... and marketer of minimally invasive ophthalmic products, today announced ... to review the Company,s recent financial results and business ... Surgical will present at the 38 th Annual ... at the Westin Waterfront Hotel on Wednesday, ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3STAAR Surgical To Present At Upcoming Investor Conferences 2
... from Cytel join peers in examining the rise of ... ... CAMBRIDGE, Mass., June 23 Cytel,s renowned adaptive,trial design and implementation ... will lead workshops and case,study reviews at the Annual Meeting of ...
... 23 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) ... Annual Scientific Meeting of,the American Headache Society, which ... Boston, MA. The oral platform abstract presentation,"Inhaled Loxapine, ...
Cached Medicine Technology:Cytel's Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting 2Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting 2
(Date:5/21/2013)... Modern couples have countless strains on ... Sexuality and Relationship Workshops, couples are learning the ... habits for their relationship. There are both private ... individuals at Texas Counseling. Their goal is to ... to develop long term solutions. , Developing ...
(Date:5/21/2013)... Department of Defense Serum Repository (DoDSR), University of Cincinnati ... inflammatory bowel disease (IBD), which could help with earlier ... shown symptoms. , This finding, the first of its ... being presented via podium presentation by staff from Walter ... 2013, being held May 18-21 in Orlando, Fla. ...
(Date:5/21/2013)... 21, 2013 The Las Vegas personal injury ... announce that Crawford Gates, a senior at Coronado High School, ... scholarship essay contest . As the winner of the essay ... contest started on Dec. 1, 2012 and ran through April ... submit a three-page minimum essay on “The Role of the ...
(Date:5/21/2013)... May 21, 2013 A new study ... Medicine indicates that stem cells harvested from fat (adipose) ... in helping to modulate the body’s immune system. ... new stem-cell-based therapies, as adipose tissue-derived stem cells (AT-SCs) ... found in bone marrow and can be collected from ...
(Date:5/21/2013)... Australia (PRWEB) May 22, 2013 About ... made the Fertility Clinics industry one of ... industry assists patients who are unable to conceive naturally ... and popular of which is in-vitro fertilisation (IVF) cycles. ... IVF cycles in Australia has increased by 4.4% per ...
Breaking Medicine News(10 mins):Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 3Health News:Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld 3
... 24 (HealthDay News) -- Morbidly obese patients who undergo spinal ... and also face higher hospital costs, a new study says. ... spinal pain. People with a body mass index (BMI) of ... generally 50 to 100 percent over their ideal body weight, ...
... , WEDNESDAY, May 23 (HealthDay News) -- The risk of ... travel more slowly through the lower chambers of the heart, ... heart and cause it to pump blood through its four ... be measured using an electrocardiogram (ECG). The waves traveling through ...
... the most comprehensive analyses to date of the cost of ... that this now-dominant surgical approach is significantly more costly than ... patient outcomes. The results of the study are available online ... Urology . In one of the first ...
... that maintain healthy nerve connections as we age help keep ... charity Age UK has found. Older people with robust ... different, distant brain areas can process information quickly and ... According to the findings, joining distant parts of the ...
... , WEDNESDAY, May 23 (HealthDay News) -- The ... reduced through a multi-pronged approach that includes more training ... to a new German study. Despite legal regulations ... as bed rails and belts still are frequently used ...
... Minn. -- Mayo Clinic researchers will present findings on ... at the annual meeting of the American Urological Association ... be available to provide expert comment for reporters covering ... presented and their embargo dates include: No ...
Cached Medicine News:Health News:Severely Obese Have More Complications With Spinal Surgery 2Health News:Study Spots Early Warning Signal for Sudden Cardiac Death 2Health News:Robotic-assisted prostate cancer surgery drives up costs, UPMC study finds 2Health News:Robotic-assisted prostate cancer surgery drives up costs, UPMC study finds 3Health News:Well-connected brains make you smarter in older age 2Health News:Study Offers Ways to Decrease Use of Restraints at Nursing Homes 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
Maximum contact. Minimum wear. Outstanding results....
...
...
Medicine Products: